BioRestorative suspends ExoCR and BioX product shipments

BioRestorative Therapies, Inc. reported that on August 7, 2026 it suspended, effective immediately, all orders and shipments of its biocosmeceutical product lines, including its ExoCR and BioX products, pending a business review and regulatory assessment.

Rhea-AI Filing Summary

BioRestorative Therapies, Inc. reported that on August 7, 2026 it suspended, effective immediately, all orders and shipments of its biocosmeceutical product lines, including its ExoCR and BioX products, pending a business review and regulatory assessment. The company stated it has not decided to discontinue these product lines and is reviewing documentation, sourcing, and the regulatory status associated with them. The company noted that outcomes of this review, its ability to resume sales, related costs, and its capital needs are subject to significant risks and uncertainties described in its prior SEC reports.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

biocosmeceutical, regulatory assessment, forward-looking statements

3 terms

biocosmeceutical technical

"suspended, effective immediately, all orders and shipments of its biocosmeceutical product lines"

A biocosmeceutical is a skin or beauty product that combines cosmetic appeal with biologically active ingredients derived from biotechnology or biological sources, aiming to produce measurable effects such as reduced wrinkles, improved hydration, or clearer skin. For investors, these products matter because they often require more research, testing and regulatory attention than ordinary cosmetics, can command higher prices, and may create competitive advantages similar to a tech upgrade in a familiar consumer product.

regulatory assessment regulatory

"pending a business review and regulatory assessment"

forward-looking statements regulatory

"contains forward-looking statements within the meaning of Section 27A"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioRestorative Therapies (BRTX) announce on August 7, 2026?

BioRestorative Therapies suspended all orders and shipments of its ExoCR and BioX biocosmeceutical product lines, effective immediately, while it conducts a business review and regulatory assessment of those products.

Which BioRestorative Therapies (BRTX) products are affected by the suspension?

The suspension covers all biocosmeceutical product lines, specifically the company’s ExoCR products and BioX products, with all orders and shipments halted during the ongoing business and regulatory review.

Has BioRestorative Therapies (BRTX) decided to discontinue ExoCR and BioX products?

No. The company stated it has not made a decision to discontinue the ExoCR and BioX product lines and is currently reviewing documentation, sourcing, and regulatory status before determining any further actions.

Why did BioRestorative Therapies (BRTX) suspend its biocosmeceutical product lines?

The suspension was implemented to allow a business review and regulatory assessment of the ExoCR and BioX biocosmeceutical products, including examination of their documentation, sourcing, and regulatory status.

What risks did BioRestorative Therapies (BRTX) highlight related to the product suspension?

The company cited risks including the outcome of the review, its ability to resume sales, the costs of the suspension, potential need for additional capital, and other risk factors in its prior SEC reports.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:23 PM Accepted by SEC EDGAR 08/14/2026 - 04:15 PM Learn about SEC filing dates

false 0001505497 0001505497 2026-08-07 2026-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: August 7, 2026

(Date of earliest event reported)

BIORESTORATIVE THERAPIES, INC.

(Exact Name of Registrant as Specified in Charter)

Nevada		001-37603		30-1341024
(State or Other Jurisdiction of Incorporation)		(Commission File No.)		(IRS Employer Identification Number)

40 Marcus Drive, Melville, New York		11747
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (631) 760-8100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		BRTX		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On August 7, 2026, BioRestorative Therapies, Inc. (the “Company”) suspended, effective immediately, all orders and shipments of its biocosmeceutical product lines, consisting of its ExoCR products and its BioX products, pending a business review and regulatory assessment. The Company has not made a decision to discontinue these product lines.

The Company is conducting a review of the documentation, sourcing, and regulatory status associated with these products.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the Company’s business review and regulatory assessment, the potential outcomes of that review, and the status of the Company’s biocosmeceutical product lines. These statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the outcome of the review, the Company’s ability to resume sales of the affected product lines, the costs associated with the suspension, the Company’s need for additional capital, and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and its subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIORESTORATIVE THERAPIES, INC.
Date:	August 14, 2026
By:	/s/ Katharyn Field
Name:	Katharyn Field
Title:	Director, Chief Executive Officer, President and Interim Chief Financial Officer

Page 3 of 3

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.9 KB